Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) EPS (Basic) (2016 - 2019)

Alterity Therapeutics has reported EPS (Basic) over the past 3 years, most recently at -$3.45 for Q4 2018.

  • For Q4 2018, EPS (Basic) rose 35.24% year-over-year to -$3.45; the TTM value through Jun 2019 reached -$8.77, down 11.82%, while the annual FY2025 figure was -$0.12, 63.89% up from the prior year.
  • EPS (Basic) for Q4 2018 was -$3.45 at Alterity Therapeutics, up from -$5.32 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$2.52 in Q4 2016 and troughed at -$5.32 in Q4 2017.
  • A 3-year average of -$3.76 and a median of -$3.45 in 2018 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): crashed 111.23% in 2017 and later surged 35.24% in 2018.
  • Year by year, EPS (Basic) stood at -$2.52 in 2016, then crashed by 111.23% to -$5.32 in 2017, then surged by 35.24% to -$3.45 in 2018.
  • Business Quant data shows EPS (Basic) for ATHE at -$3.45 in Q4 2018, -$5.32 in Q4 2017, and -$2.52 in Q4 2016.